Abstract The therapeutic bene®t of adding interferon a (IFNa) to established single-agent and combination chemotherapy regimens for the treatment of metastatic melanoma has not been proven. We designed the present study to estimate the response rate of IFNa, dacarbazine, cisplatin and tamoxifen in patients who had not been treated with systemic therapy for advanced disease. Using a schedule similar to that which had previously been shown to favor IFNa plus dacarbazine over dacarbazine alone, we treated patients with aǹ`i nduction'' regimen of IFNa, 15 mU m A2 day A1 intravenously 5 days/week for 3 weeks. Following induction, schedules of IFNa, 5 mU m A2 day A1 subcutaneously three times a week, and tamoxifen, 10 mg orally twice a day, were begun. Dacarbazine, 250 mg m A2 day A1 and cisplatin 33 mg m A2 day A1 for 3 consecutive days were repeated every 4 weeks, and subcutaneous IFNa and oral tamoxifen were continued until the discontinuation of chemotherapy. We treated 25 patients (18 men and 7 women, median age 52 years) and observed only 1 objective response (response rate 4%, 95% con®dence interval 0.1%±20%). The toxicities of the regimen consisted of moderate myelosuppression and constitutional side-eects. On the basis of the low antitumor activity of this regimen, we do not recommend it for further study or for use as standard therapy of metastatic melanoma.
Introduction
The addition of biological response modi®ers such as interferon a (IFNa) to selected chemotherapeutic agents has additive or even synergistic eects in preclinical models of human solid tumors (Wadler and Schwartz 1990) . The therapeutic bene®t of adding biological response modulators to chemotherapy for the treatment of patients with advanced melanoma has not been proven, although the results of small randomized and nonrandomized studies have suggested the superiority of aggressive biochemotherapy combinations over either component alone (Legha et al. 1998; Richards et al. 1992; Atkins et al. 1994; Khayat et al. 1993; Keilholz et al. 1997 ).
The results of phase II studies showed encouraging activity for combinations of IFNa and dacarbazine [5-(3,3-dimethyl-1-triazenyl )-1H-imidazole-4-carboxamide, DTIC] (Hersey et al. 1991; Bajetta et al. 1990 ), but randomized studies did not provide a de®nitive conclusion as to the bene®t of adding IFNa to dacarbazine (Thomson et al. 1993; Bajetta et al. 1994 ). However, a subsequent phase III trial of intravenous IFNa, administered daily 5 days/week for 3 weeks, followed by dacarbazine and thrice-weekly subcutaneous IFNa showed a signi®cantly improved objective response rate of 53% with the combination, compared to only 20% with dacarbazine alone. Complete responses were seen only in patients assigned to the combination regimen. The rationale for the dose and schedule of IFNa was to achieve exposure to high peak levels followed by continuous exposure to the biological agent while safely combining it with dacarbazine at full doses (Falkson et al. 1991) .
We designed the present study to evaluate the feasibility of combining IFNa with dacarbazine, cisplatin and tamoxifen, using the same sequence of IFNa and chemotherapy as used in that trial. The chemotherapy combination was based on a series of Southwest Oncology Group (SWOG) regimens evaluating dacarbazine and cisplatin alone (Fletcher et al. 1993) or with tamoxifen (Flaherty et al. 1996) , a modulator that has been considered critical for the optimal antitumor activity of one or more of the active drugs (McClay et al. 1989) . Although nitrosoureas are often incorporated into combination chemotherapy for advanced melanoma, their precise role has never been ®rmly established in prospective trials, and we felt that the prolonged myelosuppression associated with N,N ¢ -bis(2-chloroethyl)-N-nitrosourea, particularly the risk of cumulative thrombocytopenia, would make it dicult to combine with continuous IFNa. We sought to identify an active and tolerable regimen that could subsequently form the basis of a randomized study to determine the bene®t of combining IFNa with chemotherapy in the treatment of advanced melanoma or in the adjuvant setting.
Patients and methods

Patient eligibility
The eligibility criteria for this trial included the following clinical parameters: histological diagnosis of melanoma with measurable metastatic disease, a SWOG performance status of 1 or lower, no history of seizure disorder or central nervous system metastasis (brain computed tomographic or magnetic resonance imaging required), no prior therapy with any of the agents in the regimen (except adjuvant IFNa if completed at least 12 months prior to relapse), and no active infection or anticipated need for glucocorticoid therapy. Patients with a history of serious ventricular arrhythmia, congestive heart failure, poorly controlled angina pectoris, or other severe cardiovascular disease were excluded. At least 28 days had to have elapsed since prior radiation therapy, and the patient had to have recovered from any prior surgery. Patients were allowed one prior chemotherapy for advanced disease. Laboratory parameters were as follows: serum bilirubin at or within the institutional upper limit of normal, alanine aminotransferase at or within 2.5´the institutional upper limits of normal (£5´the institutional upper limits of normal if the liver was involved with tumor), granulocytes at least 1800/ll, platelet count at least 150 000/ll, and hemoglobin at least 10 g/dl; serum creatinine had to be within normal limits and the estimated or measured creatinine clearance at least 60 ml/min. Tumor measurements were performed within 28 days of study registration. All patients provided their voluntary, written informed consent to participate in the study, which was approved by the institutional review boards of each of the participating institutions.
Treatment
Treatment was administered in the inpatient or outpatient units of the participating institutions to assure adequate hydration and management of the volume and electrolyte status of the patients. Antiemetic therapies were at the treating physician's discretion, but corticosteroids were excluded. Treatment was initiated with IFNa alone, 15 mU m A2 day A1 , intravenously (i.v.) 5 days/week for 3 weeks; this was followed by chemotherapy consisting of dacarbazine, 250 mg m A2 day A1 i.v., and cisplatin, 33 mg m A2 day A1 i.v., on days 1±3. Tamoxifen, 10 mg orally, twice daily, was begun with chemotherapy and continued throughout protocol treatment. IFNa was resumed at 5 mU/m 2 subcutaneously (s.c.), three times weekly, on the ®rst day of chemotherapy and continued throughout protocol treatment.
Chemotherapy cycles were repeated every 4 weeks in responding and stable patients who continued to meet parameters for treatment (see below). The maximum duration of therapy was 1 year. During protocol therapy, patients were required to undergo the following clinical and laboratory examinations: a weekly complete blood count; electrolytes, creatinine, urinalysis and liver function tests; biweekly physical examination and toxicity assessments (using the National Cancer Institute Toxicity grading criteria). The creatinine clearance was measured or calculated prior to each chemotherapy cycle.
Guidelines for dose adjustments of the therapeutic agents and the use of colony-stimulating factors after the ®rst cycle of therapy were as follows: IFNa could be continued despite grade 1 toxicity; for IFNa-related toxicities of grade 2 or more, IFNa was to be held until all toxicities resolved to grade 1 or less, followed by resumption of therapy at 50% of the prior dose. Dose re-escalations were not permitted. If toxicity of grade 2 or more recurred at the decreased dose, the patient was to be taken o IFNa and could be continued on chemotherapy. Cisplatin dose adjustments were provided for renal impairment and peripheral neuropathy. Dacarbazine doses were adjusted for nadir and treatment-day cytopenias, and treatment could be delayed up to 2 weeks to allow sucient recovery for full dose administration. Granulocyte-colony-stimulating factor (G-CSF) was to be added in the event of fever with neutrophils at 1000/ll or less, in which case the dacarbazine dose for the following cycle was to be decreased by 25% and 5 lg/ kg G-CSF used prophylactically on days 4±9 (or until the neutrophil count was at least 1500/ll for 3 consecutive days). Guidelines were also provided for management of thromboembolic complications from tamoxifen, but no such episode was observed in this study.
Evaluation of response
The de®nitions of response were as previously described for Southwest Oncology Group studies (Green and Weiss 1992) . Scans for tumor assessment were to be repeated after every two cycles. For con®rmation of the response status, a repeat tumor assessment was required 4 weeks following the ®rst achievement of response. The maximum duration of therapy was 1 year. Patients achieving complete response were to receive two additional treatment cycles following con®rmation of complete response. Patients who showed evidence of disease progression after the initial IFNa but prior to chemotherapy were allowed to remain on-study as long as they continued to meet the eligibility criteria.
Statistical design
The primary objective of this pilot study was to assess the antitumor activity of the regimen, which would be considered worthy of further study if the true response rate was 35% or more and not of interest if it was below 20%. The study was designed to accrue 60 patients in a single stage. Out of 60 patients, 18 responses would represent evidence of antitumor activity worthy of further pursuit and would reject a response rate of 20% or less at a one-sided 0.05 level of signi®cance (or better) and provide a power of 83% or more to detect a true response rate of at least 35% (Green and Dahlberg 1992) . The second objective was to evaluate the toxicity and tolerability of the regimen. It would be considered unacceptable for standard use or for inclusion in a phase III trial if either (a) more than 60% of patients experienced grade 3 or worse nonhematological toxicity or thrombocytopenia during the i.v. IFNa treatment, or (b) more than 60% of the patients required the discontinuation of i.v. IFNa during the ®rst treatment cycle.
Results
Patient characteristics
Between August 1994 and November 1996, 26 patients were accrued at nine Southwest Oncology Group Institutions. One patient was found to be ineligible because of missing study documentation. Patient characteristics are listed in Table 1 . Of the 25 eligible patients, there were 18 men and 7 women, and the median age was 52 years (range 17±75 years). Twenty-three patients were Caucasian, 1 was black and 1 Hispanic. Thirteen patients had performance status 0 and 12 had performance status 1. Only 2 patients had metastatic disease limited to skin and/or soft tissue/lymph nodes, and the rest had visceral involvement [liver, 6 (24%); lung, 18 (72%); bone, 3 (12%)]. No patient had received previous chemotherapy or biological response modi®ers.
Although a formal two-stage accrual design was not part of the original statistical plan, we had the opportunity to analyze the data after the ®rst 26 patients, when a national shortage of dacarbazine occurred. Although the toxicity level of this regimen did not exceed that which was allowable by the criteria detailed above, there had been only a single con®rmed objective response among the ®rst 26 patients (95% con®dence interval £20%), so we elected to close the study to further accrual.
Treatment administered
Although organ toxicities requiring dose adjustment were rare (Table 2) , administration of IFNa was often limited by constitutional side-eects (fever, myalgias, severe fatigue, nausea, and anorexia). Seventeen patients (68%) received all of the i.v. IFNa planned for cycle 1, but only 6 (24%) received 100% of the planned i.v. and s.c. IFNa; 11 patients (44%) completed all of the i.v. IFNa but required dose reductions of s.c. therapy, and 3 (12%) discontinued the i.v. phase early but completed the planned s.c. dosing; 5 patients (20%) required dose adjustments of both phases of therapy.
The median duration of protocol therapy was 3 months, corresponding to``induction'' plus two cycles of combination therapy, and the predominant reason for going o study was disease progression (in 15 patients, 60%). The other reasons for discontinuation of protocol therapy were toxicity of therapy (4 patients) or patient refusal (3 patients); 3 patients were taken o study for reasons related to physician judgment or insurance limitations without progressive disease or toxicity requiring removal from study.
Toxicities of treatment
The grade 3 and 4 non-constitutional toxicities of the regimen are summarized in Table 2 and are listed separately for the initial 3-week period of intravenous IFNa and the subsequent combined chemotherapy and sub- cutaneous IFNa``biochemotherapy.'' The spectrum of toxicities was in accordance with those previously described for high-dose intravenous IFNa. The toxicities associated with the full multi-agent regimen were neither unexpected nor excessively severe, consisting mainly of nausea, mild to moderate neutropenia and thrombocytopenia, which were managed by dose adjustments and, if indicated, the institution of G-CSF according to protocol requirements.
Tumor response
There was one partial response (duration 7 months) in a man with lung metastases, among the 25 eligible patients (objective response rate 4%, 95% con®dence interval 0.1%±20%). The study was closed temporarily after 26 patients had been accrued (25 eligible) because of a national shortage of dacarbazine. Analysis of these ®rst 25 eligible patients revealed that there had been only 1 objective response, providing an exact 95% con®dence interval of 0.1%±20% for the response rate. This result was consistent with the null hypothesis of a 20% or lower response rate, while the hypothesis of a response rate of at least 35% was rejected with a P value of 0.0003. Therefore, the study was permanently closed. The median survival of the entire group was 10 months (95% con®dence interval 7±18 months).
Discussion
Current clinical investigations in melanoma therapy are focused in two main areas: the discovery of more active chemotherapeutic and/or biological molecules, and the identi®cation of the most active regimen for standard therapy, based on currently available agents. The study reported here was an attempt to combine a chemohormonal combination that had previously been studied by the Southwest Oncology Group (Flaherty et al. 1996) , with an aggressive dose and schedule of IFNa, employing a sequence that had shown promising enhancement of antitumor activity when combined with single-agent dacarbazine. (Falkson et al. 1991) Since the results of cooperative group phase II and III studies have almost invariably shown lower objective response rates than smaller, usually single-institution studies of identical regimens (Flaherty et al. 1997) , we chose to pilot the present regimen in the cooperative group setting prior to incorporating this regimen into a phase III biochemotherapy versus chemotherapy study. Participation in this trial was limited to a select group of SWOG institutions and investigators who had demonstrated capability for administering aggressive biochemotherapy combinations to patients with advanced melanoma.
The patients enrolled in this study had a signi®cant tumor burden, as evidenced by the high proportion of patients with visceral (particularly hepatic) involvement and the number of patients with a compromised performance status. All of these factors have been associated with a lower response to systemic therapy in cooperative group melanoma trials (Flaherty et al. 1997) . This factor may account, in part, for the low overall response rate in our study, despite an aggressive regimen delivered by a small group of experienced clinicians.
The apparent lack of enhanced antitumor activity resulting from the addition of IFNa to chemotherapy on this dose and schedule is consistent with the recently reported results of the Eastern Cooperative Oncology Group (ECOG), in which the addition of IFNa in the same dose and schedule as dacarbazine, with or without tamoxifen, did not enhance the objective response rate or the survival of patients with metastatic melanoma (Falkson et al. 1998) . The results of our study, initiated before the preliminary ECOG analysis (Falkson et al. 1996) , are compatible with the ®ndings of this randomized trial.
It is possible that the schedule of biochemotherapy that we used for this trial led to antagonistic rather than additive or synergistic interactions with one or both of the chemotherapeutic agents. The dependence of optimal biochemotherapy interactions on the schedule is well-described (Welander 1987 ) but has not been addressed adequately in human cancer therapy trials. We based our schedule and doses of IFNa on that which had shown superiority to chemotherapy alone in the prior randomized trial (see above). Furthermore, in the adjuvant setting, an``induction'' phase consisting of intensive intravenous IFNa followed by a relatively aggressive regimen of thrice-weekly subcutaneous IFNa, appeared to be essential for the activity of this agent in prolongation of disease-free and overall survival , while regimens consisting of lower doses and lacking an induction phase have been inactive (reviewed in Sondak and Margolin 1999) .
The results of our study do not exclude a bene®cial role for optimally scheduled addition of IFNa in combinations for advanced melanoma. This question is currently being tested by the SWOG/ECOG Intergroup in a randomized phase III trial of combination chemotherapy [the cisplatin, vinblastine, dacarbazine (CVD) regimen of Legha et al.] with or without IFNa and infusional interleukin-2 (IL-2). The chemotherapy combination chosen for this study, while never proven to be better than dacarbazine alone in a completed phase III trial, has been well-tolerated and associated with objective response rates in the range of 40% in large single-institution studies (Legha et al. 1989) . It has also been combined successfully with IFNa and IL-2 in a regimen reported to induce durable complete responses in 8%±10% of patients (Legha et al. 1998) . The goal of this new study is to compare not only the objective response rates but also the percentage of patients achieving durable complete responses, an outcome that, to date, has been reported only in trials of aggressive biochemotherapy. The results of this trial as well as ongoing innovations in the ®eld of melanoma immunotherapy will de®ne future approaches to the therapy of advanced disease and the adjuvant therapy of high-risk primary melanoma.
